Skip to search formSkip to main contentSkip to account menu
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential
TLDR
Stealth liposomes can be actively targeted with monoclonal antibodies or ligands and encapsulating active molecules, with high target efficiency and activity by synthetic modification of the terminal PEG molecule.
View on PubMed
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
View on PubMed
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel.
View on PubMed
Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
TLDR
The incorporation of C18gem-prodrug in liposomes increased the plasma half life of the drug resulting in increased accumulation in the tumor cells and a higher level of antitumoral efficacy.
View on PubMed
P characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel
TLDR
The taxanes, paclitaxel and docetaxel, are anticancer agents used in clinical trials against ovarian carcinoma, breast, lung and head / neck cancer and to eliminate these vehicles and improve the drug's antitumor efficacy, taxanes have been incorporated in liposomes.
Preparation and characterisation of taxane containing liposomes.
Synthesis of new gemcitabine prodrugs for liposome and nanoparticle encapsulation
New DSPE-PEG-Folate conjugates for liposomal drug targeting
Synthesis and characterization of a conjugate between paclitaxel-poly(ethylene glycol) and lys(8)-vasotocin analogue
Incorporation of gemcitabine prodrugs in cyanoacrylate nanospheres and nanocapsules
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License